Core Viewpoint - Jiangzhong Pharmaceutical reported a revenue of 4.22 billion yuan, a year-on-year decrease of 4.87%, while the net profit attributable to shareholders increased by 14.96% to 906 million yuan [1] Group 1: Financial Performance - The company achieved an operating income of 4.22 billion yuan, reflecting a decline of 4.87% compared to the previous year [1] - The net profit attributable to shareholders reached 906 million yuan, showing a growth of 14.96% year-on-year [1] Group 2: Strategic Measures - The company faced structural adjustment pressures within the industry during the reporting period [1] - To enhance profitability, the company implemented measures such as strengthening brand development and optimizing cost structure [1]

Investment Rating - The report maintains a "Buy" investment rating for the company [7] Core Views - The company is experiencing steady operational progress with product structure upgrades [5][6] - The revenue for H1 2025 is reported at 1.759 billion yuan, showing a year-on-year increase of 0.3%, while the net profit attributable to shareholders is 298 million yuan, up by 1% [4] - The company is focusing on optimizing its cost structure and increasing promotional investments, which has led to a slight decrease in gross margin [5] Summary by Sections Financial Performance - In Q2 2025, the company's revenue was 651 million yuan, a decrease of 4% year-on-year, with a net profit of 64 million yuan, down 13% [4] - The gross margin in Q2 2025 decreased by 1 percentage point to 63.67% due to increased promotional activities [5] Product Structure and Market Strategy - The revenue from high-end liquor (above 300 yuan) increased by 11% to 136 million yuan in Q2 2025, driven by user engagement and terminal marketing [6] - The company is focusing on refining its operations in the provincial market and enhancing resource allocation efficiency in the northwest region [7] Earnings Forecast - The company forecasts EPS for 2025-2027 to be 0.77, 0.83, and 0.92 yuan respectively, with corresponding PE ratios of 26, 24, and 22 times [7] - The projected revenue growth rates for 2025-2027 are 0.0%, 6.9%, and 9.3% respectively [9]